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ABSTRACT 
Solid lipid microparticles (SLM) made from triglycerides and waxes are promising 
colloidal systems for controlled drug delivery. In this study, new symmetrical 1,3-
diglycerides compromised of dihydroxyacetone and lipids of varying chain length 
were synthesized and used to fabricate solid lipid microparticles via a modified 
solvent-emulsification evaporation method. Particles were physically characterized in 
terms of size, surface morphology, surface charge as a function of lipid chain length.  
Scanning electron micrograph images showed that lipid particles display a distinct 
surface morphology depending on lipid chain length, with morphology transitions 
from smooth to porous structures with increasing chain length. Results of zeta 
potential measurements showed that the spheres are negatively charged and are 
susceptible to Schiff base reaction or reductive amination reaction with primary and 
secondary amines such as linear- polyethylenimine on the surface. Hydrophobic (nile 
red) and hydrophilic (rhodamine-B) model drug compounds were incorporated into 
the microparticles to determine encapsulation efficiency and in vitro release kinetics.  
Release kinetics of the hydrophobic compound nile red showed increasing release 
kinetics with increasing chain length, while microparticles incorporating the 
hydrophilic compound rhodamine-B exhibited burst release characteristics in all cases.  
These results outline the initial characterization of dihydroxyacetone-based 
symmetrical 1,3-diglycerides as new materials for controlled drug delivery. 
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CHAPTER 1. 
INTRODUCTION AND BACKGROUND 
The discovery and use of polymeric and solid lipid particles as excipients for 
the delivery of drug molecules to targeted sites at a desired rate transformed the field 
of drug delivery, and caused an emergence of a new era in patient care. Controlled 
release technology allows delivery and release of a cargo therapeutic molecule to a 
physiological environment at a designated rate. Many drugs have a narrow therapeutic 
index, therefore requiring multiple injections resulting in poor patience compliance 
and increasing the incidence of infections and hemorrhages. Use of a controlled 
release system permits improving the availability of drugs with short in vivo half life, 
and thus eliminating the need for multiple injections and reducing the possibility of 
side effects. 
A diverse collection of natural and synthetic biodegradable polymers have 
been studied intensively for drug targeting and prolonged drug release. Natural 
biodegradable polymers such as human serum albumin, and collagen are limited in use 
because of high cost and their disputed purity, thus in last two decades, use of 
synthetic biodegradable polymers in drug delivery has increased considerably. 
Synthetic biodegradable polymers ranging from polyesters, polyanhydrides, 
poly(amides), poly(amino acids), poly(orthoesters), poly(urethanes) and 
poly(acrylamides) have been widely utilized to prepare drug loaded devices [1-3]. 
Among the most popular synthetic biodegradable polymers are thermoplastic aliphatic 
poly(esters) like poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and most 
importantly poly(lactic-co-glycolic acid) (PLGA). PLGA is approved by Food and 
Drug Adminstration (FDA) for use as implants (Zoladex
®) and microparticles 
(Decapeptyl
®, Enantone Depot
®) for treatments of prostate cancer. Encapsulation of   2
therapeutic molecules inside solid matrices not only decreases the toxicity of free drug 
molecules in the blood stream, but also allows targeted delivery through surface 
modification of these particles via covalent or electrostatic attachment of certain 
moieties (sugars, amino acids, lipids, etc). Examples of surface functionalization for 
polymeric and lipsomal particle systems range from the conjugation of PEI to the 
surface of PLGA microspheres for delivery of plasmid DNA, to surface 
functionalization of PLGA-b-PEG nanoparticles with RNA aptamers targeted toward 
treatment of prostate cancer cells [4]. 
Despite the considerable growth in this field, the costly large scale production 
and stringent FDA manufacturing regulations remains a substantial challenge [5]. In 
case of polymer based particles, despite their advantages of robust surface chemistry, 
and wealth of possible chemical modifications, the cytotoxicity associated with 
product resulting from subsequent degradation and scale up production continues to be 
an issue of pressing importance [6]. 
  In an effort to overcome the above difficulties, researchers have aimed to 
design a particulate system that is cost effective for large scale production and at the 
same time meets the FDA regulations. This carrier system needs to be physically 
stable whilst miscible with a wide variety of drugs and is easy to produce and cost 
effective. With that framework in mind, in the past decade, physiological lipids (i.e. 
triglycerides, cholesterol) have drawn significant attention as alternative materials to 
polymeric and liposomal systems, due to their potential advantages especially in terms 
of low toxicity and biocompatibility [7].  
The term lipid applies a broad family of triglycerides, partial glycerids, fatty 
acids, steroids, and waxes. There is a vast variety of literature and reviews on use of 
lipids as drug delivery carriers; however, there are not that many studies focused on 
potentials of diglycerides in specific compared to rest of the lipids family   3
(i.e.triglycerides). Solid lipid microparticles (SLM) are reportedly used to encapsulate 
various drugs such as clobetasol (anti itch, for treatment of skin inflammation) and 
GnRH antagonist (hormones) as well as used to encapsulate hepatitis B surface 
antigen for mucosal delivery against hepatitis-B [6, 8-11]. 
Solid lipid particles are derived from lipids that are solid at room temperature 
as well as at body temperature and are stabilized by surfactants. The lipids include 
highly purified triglycerides, complex glyceride mixtures and waxes [12]. While lipid 
particles offer excellent physical stability, protection of the incorporated drug from 
degradation, and controlled drug release in addition to good tolerability, they suffer 
from drawbacks such as low drug encapsulation and drug expulsion after polymorphic 
transition during storage [13].  
In this study we report synthesis of symmetrical 1,3-diglcycerides based upon 
dihydroxyacetone (DHA). DHA is a constituent of glycolysis pathway, and is FDA 
approved for oral and topical administration, making it an attractive starting material 
for the synthesis of new biomaterials and facilitating their translation into clinical 
practice [14-16]. The advantages of using DHA-derived biomolecules lies in the fact 
that once degraded the resulting molecules are eliminated via its metabolic pathway 
(Creb cycle). This study intends to describe initial experimental results of synthesis 
and use of symmetrical 1,3-diglyceries and their associated features, applied 
production methods, drug incorporation and drug release mechanism as well as 
surface modification. 
Modifying a synthetic route originally established by Bentley and McCrae[17], 
a set of six lipids with varying chain length were synthesized and used to produce 
particles in micron range In this paper, in vitro control release kinetics, zeta potential, 
as well as particle size and morphology were investigated as a function of lipid chain 
length. The presence of adjustable lipid chain length thus changeable degradation rate   4
makes room for tailor made drug delivery carriers that can be modified depending on 
the nature of the encapsulating drug, taking us one step closer to individualized 
medicine.   5
CHAPTER 2. 
SPECIFIC AIMS 
The objective of this study is to understand how the rate of release of an 
encapsulated model drug correlates as a function of the lipid chain length, our working 
hypothesis is that rate of release will increase with the decrease in lipid chain length. 
The following specific aims are defined to evaluate our hypothesis: 
 
1. To synthesize DHA-derived symmetrical 1,3-diglycerides. Using a synthetic 
route modified from Bentley and McCare [17], an array of symmetrical 1,3-
diglycerides will be synthesized in high yields, and their characterization will entail 
1H 
NMR spectroscopy and elemental analysis. 
2. To fabricate solid lipid particles. Particles will be made using solvent-
emulsification/evaporation method, and will be characterized in terms of size, charge 
and morphology.  
3. To characterize the rate of release of model drug as a function of lipid chain 
length. The in vitro controlled release behavior will be studied through encapsulation 
of a range of model drugs with varying range of hydrophobicity and hydrophilicity. 
Our working hypothesis is to find a correlation between encapsulation efficiency and 
the nature of model drug as well as lipid chain length. 
 
The investigation of these specific aims will provide us with a detailed general 
background knowledge of symmetrical 1,3-diglycerides as solid lipid particles in 
preparation for more advanced encapsulation and in vitro release study.   6
CHAPTER 3. 
METHODS OF LIPID PARTICLE PRODUCTION 
There are various methods to make lipid particles and the choice of the 
technique is contingent upon the nature of the lipid, the encapsulating drug, as well as 
the intended use. 
3.1.1 Preparation by solvent emulsification-evaporation  
In the solvent emulsification technique, lipid is dissolved in a water-immiscible 
solvent (i.e. chloroform, toluene), emulsified in an aqueous surfactant solution, 
followed by evaporation of the organic solvent yields lipid particles (Figure 1). An 
advantage of this technique is the absence of high temperature, making it a suitable 
method for heat sensitive drugs; however, the draw back of residual organic solvents 
still remains. In the solvent diffusion technique, the lipid is dissolved in a partially 
water-miscible organic solvent and then emulsified in an aqueous surfactant solution. 
The diffusion rate of the water-miscible solvent to aqueous phase is very rapid, thus 
causing turbulence at the interface between organic solvent and aqueous phase. The 
turbulence, referred to as Marangoni effect [18], leads to assembly of PVA molecules 
around emulsion droplets, setting off spontaneous droplet formation. The reduced 
solubility of lipid drug complex at the emulsion interface causes immediate 
precipitation of lipid and accompanying drug thus encapsulating drug inside the lipid 
matrix with organic solvent diffusing out toward the continuous phase. The 
dispersions are fairly dilute and particles can be collected via filtration or 
centrifugation [12, 19]. This method is widely utilized for encapsulation of 
hydrophobic drugs, however depending on the nature of the drug, low encapsulation 
efficiency maybe a problem at which point the process is modified/changed increase 
encapsulation efficiency.   7
 
 
 
 
 
 
 
 
 
 
Figure 1: Solvent emulsification evaporation method 
3.1.2. High pressure homogenization (HPH) 
There are two methods of high pressure homogenization, hot and cold. In hot 
HPH, lipid and drug are melted together at approximately 5 
oC above the lipid melting 
point; the melt is mixed with aqueous surfactant solution (i.e. poly (vinyl alcohol)) at 
the same temperature. The hot pre-emulsion solution is stirred at high speeds and then 
processed with a temperature controlled homogenizer. The process is followed by 
cooling to room temperature and crystallization of lipid particles. In cold HPH, the 
melt containing molten lipid and drug is ground under a stream of liquid N2, leading to 
formation of lipid microparticles. The presuspension is stirred in a cold aqueous 
surfactant solution followed by homogenization. The advantages of HPH technique 
are the narrow particle size distribution as well as absence of any organic solvents 
[12]. The advantage of this method is that there are no organic solvents involved, 
however this method is limited to temperature insensitive drugs. 
   8
3.1.3. Preparation by Water-in-oil-in-water ( w/o/w) double emulsion method 
In w/o/w double emulsion technique is a modification of solvent 
emulsification-diffusion method specifically aimed at encapsulating hydrophilic drugs. 
In this method, the drug is solubilized in an internal aqueous phase of a w/o/w double 
emulsion, along with a stabilizer to retard drug loss to the external aqueous phase 
during solvent evaporation [20]. High speed stirring and/or ultrasonication can also be 
utilized to yield lipid particles. Particles can be collected through ultra filtration as 
well as centrifugation.  
3.1.4. Preparation using other methods 
  Other preparation methods such as microchannel emulsification technique 
[21], spray congealing, and cryogenic micronisation are also utilized. Particle prepared 
using microchannel emulsification are prepared through forced flow of that dispersed 
phase through a continuous surfactant phase, the resulting particles are reportedly 
monodisperse and the size of the droplet is dependent on the design of the 
microchannel [13].  
3.2. Methods of analytical characterization of lipid particles 
Extensive characterization of lipid particle properties made through various 
methods provides us with the opportunity to select a method depending on the costs, 
desired particle size distribution, and recovery efficiency.  
3.2.1 Size measurements 
Size is one of the deciding factors for pharmaceutical applications and 
characteristics of well-formulated system will include a narrow size distribution. 
When it comes to delivery of drugs via intravenous injections, particles larger than 5- 
μm can cause embolism [22]. In addition, the size of the particles can trigger the   9
capture mechanism though phagocytosis, a process in which large and insoluble 
particles are enveloped by the plasma membrane and internalized [23], subsequently 
influencing the bioavailability of the drug encapsulated particles. Particle size 
measurements are usually done using dynamic light scattering (also known as photon 
correlation spectroscopy (PCS)) and laser diffraction (LD) for particle size spanning 
nanometers to 5-6 μm, for particles larger than 6 μm, Coulter counter method [24] in 
which the electrical resistance produced by particles suspended in buffer solution, 
while passing through an aperture, is usually utilized. The resulting displaced volume 
of buffer solution, which is proportional to the particle size will create a voltage pulse 
that is collected to create a particle size distribution [25]. 
3.2.2 Charge measurements 
Zeta potential ζ  is an assessment of the surface charge of colloidal dispersion 
and often the key to understanding dispersion and aggregation in particle population. 
The greater the zeta potential ( ζ ) the less likely the suspension is to become 
unstable, because charged particles repel one another and therefore overcome the 
tendency to aggregate [22]. Surface charge is measured using a zeta sizer which 
measures the electrophoretic mobility across the diffusive layer of the particles. 
3.2.3 Morphology 
  Particle morphology, studied using scanning electron microscopy (SEM), is an 
indicative of particle composition and origin and it also serves to better the 
understanding of in vitro controlled release in case of drug encapsulated particles. 
Particles with higher surface:volume ratio allow more buffer access and deeper 
penetration thus a faster degradation rate. Particle morphology also has an impact on 
the recognition process by the cells, thus becoming an important characteristic [26].   10
3.2.4 Encapsulation efficiency 
Encapsulation efficiency (EE) is defined as percentage of drug experimentally 
encapsulated over the amount the drug originally fed into the system whilst it being a 
function of preparation method it is also a function of the hydrophilic/hydrophobic 
nature of the drug, for example O/W emulsion technique is often used for 
encapsulation of hydrophobic drugs while W/O emulsion is utilized to encapsulate 
hydrophilic drug [13]. In a study done by Cortesi et al.. encapsulation of hydrophobic 
drug in the matrix, using the melt dispersion method was as low as 2% compared to 
70% encapsulation efficiency in case of hydrophobic drug prepared using the same 
technique. In an effort to increase encapsulation efficiency, the preparation method of 
the lipid particle was changed to w/o/w double emulsion and the subsequent efficiency 
was raised to 50% [20].  
3.3. Drug release from lipid particles 
   Kinetics of drug release is an important aspect of the particle characterization. 
In vitro release gives an insight into the drug distribution inside the matrix as well as 
information about the release mechanism. It has been shown that the release profile is 
primarily influenced by modification on the lipid matrix, surfactant concentration and 
fabrication parameters [27, 28]. Wissing et al. [12] proposed the following structural 
models for drug encapsulated lipid particles, 
   11
Figure 2: Proposed structural models for drug-containing lipid particles [12] 
Depending on the nature of the encapsulated drug and method of preparation, the three 
primary outcomes are: a drug enriched core particle, a drug enriched shell or a particle 
with drug homogenously dispersed throughout the matrix. Those particles with drug 
enriched shell often display a burst release behavior rather than sustained release over 
an extended period of time. Also, depending on the particle size, those enriched on the 
surface often display rather low encapsulation efficiency.  
3.4. Surface Modification of particles 
Surface modification of drug encapsulated particles for targeted delivery to 
specific cell types would greatly enhance the effectiveness of drug delivery by these 
vesicles [4, 29, 30]. In the case of polymeric particles, some examples of surface 
modification include PEGylated particles that have shown great potential as long 
circulating systems for intravenous injections and polyetheylenimine (PEI)-conjugated 
PLGA microspheres [29] which are strong contenders in field of gene delivery to 
cells. Some other examples of surface modified particles are, PLGA-b-PEG 
nanoparticles functionalized with aptamers [4] utilizing EDC (1-ethyl-3-(3-
dimethylaminopropyl) cabodiimide hydrochloride)/NHS chemistry. These surface 
modified particles were then recognized by antigens expressed on the surface of   12
prostate cancer cells. Similarly Kasturi et al. [30] employed a modified EDC/NHS 
chemistry to conjugate PEI to the surface of PLGA microspheres, yielding cationic 
microparticles useful for delivery of plasmid DNA.  
However, examples of surface modified lipid particles are scarce especially in 
the case of mono- and diglycerides, and their ability as alternative surface modified 
carriers for drug delivery remains in question. But nevertheless, it has been shown that 
lipid particles combine the virtues of liposomes and polymeric particles in a sense that 
they are biodegradable, can incorporate hydrophobic/hydrophilic drugs, and have an 
enhanced stability of the incorporated drugs, and are deemed more feasible for scale-
up [6].   13
CHAPTER 4. 
MATERIALS AND METHODS 
4.1. Materials 
1,3-Dihydroxyacetone dimer (DHA), palmitoyl chloride, myristoyl chloride, and 
lauroyl chloride, as well as anhydrous pyridine, sodium cyanoborohydride and 
chloroform were all obtained from Sigma-Aldrich and used without further 
purification. Poly(vinyl alcohol) (PVA, MW∼25000, 88 mole% hydrolyzed) and 
polyethylenimine-linear (PEI, MW∼25000) were purchased from Polysciences Inc. 
Dichloromethane(DCM), acetone, tetrahydrafuran(THF) and ether were purchased 
from J.T.Baker. Rhodamine-B was purchased from Fluka. 
4.2. Synthesis of symmetrical 1,3-diglycerides 
 Symmetrical  1,3-diglycerides were synthesized through modification of a 
previously reported method by Bently and McCrae [17]. The general procedure is as it 
follows: dihydroxyacetone (DHA) is stirred in chloroform under flow of N2 at room 
temperature, and acyl chloride and anhydrous pyridine are added drop wise in that 
order to the heterogeneous mixture, respectively. The mixture is stirred for 3 hrs 
followed by extraction of chloroform layer with water portions. Chloroform is 
evaporated using rotary evaporation and the remaining solid is re-crystallized using 
methylene chloride-ether combination. 
1H-NMR spectra were recorded at room 
temperature with a Brucker AF-300 spectrometer operating at 300.13 MHz.   14
 
 
 
 
 
 
 
Scheme 1: Reaction pathway for synthesis of symmetrical 1,3- diglycerides 
4.3. Fabrication of Solid Lipid Microparticles (SLM) using spontaneous 
emulsification-solvent evaporation method 
Lipid (0.1 gm) is dissolved in a 3:2 ratio of DCM:acetone by vigorous vortexing for 
approximately 10 seconds. The lipid solution was poured into 450 ml of 2.5% PVA 
solution stirring at 800 rpm and left for 3 hrs to allow full evaporation of all organic 
solvents. Particles were separated by centrifugation followed by multiple washes (3×) 
with water. The particles were resuspended in de-ionized water and lyophilized for a 
minimum of 12 h and were stored at -20
oC. The results were fine powder particles 
with approximate yield of 75% (relative to original weight of lipid). The fabrication 
variables that were examined are provided in Table 1. 
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Table 1: Summary of modified solvent emulsification-evaporation method for 
concentration CA and CB lipid solution 
4.4. Particle characterization 
Particle morphology as well as size was studied at low voltage (5 kV) using 
scanning electron microscopy imaging (LEICA 440) after coating with palladium. The 
samples were suspended in 1:10 diluted Phosphate buffer saline and surface charge 
was investigated using a Malvern Zetasizer-Nano ZS (Malvern, UK). 
4.5 Surface Modification using Linear-PEI 
PEI (31mg: 581μmol) and (30 μmol) of lipid microspheres were incubated in 5 
ml of sodium borate buffer (pH 8.5). After addition of sodium cyanoborohydride (5 
equiv/lipid), the reaction was incubated for 4 hrs at 40 
oC. At the end of the reaction 
duration, particles were washed 4× in excess 1M NaCl solution [30] to remove 
physically adsorbed PEI. Afterward, particles were resuspended in 1:10 dilution of 
PBS buffer and zeta potentials was measured in triplicates.  
 
Method Disperse  Phase  Dispersion 
Medium 
Stirring 
speed 
Process 
duration 
Particle 
isolation 
 
Emulsification-
solvent evaporation 
CA 
 
Dissolved Lipids 
(0.1gm) in 5 ml of 
3:2 ratio of 
DCM:Acetone 
CA=[0.02] gm·ml
-1 
 
2.5 and 5 wt% 
poly(vinyl 
alcohol) 
800 rpm 
at 25
oC  1.5 hrs 
Centrifugation 
followed by 
washing 
Emulsification-
solvent evaporation 
CB 
Dissolved Lipids 
(0.1gm) in 10 ml 
of 3:2 ratio of 
DCM:Acetone 
CB=[0.01] gm·ml
-1 
 
 
2.5and5 wt% 
poly(vinyl 
alcohol) 
800 rpm 
at 25
oC 
3 hrs 
 
Centrifugation 
followed by 
washing   16
 
HN
NH
n
PEI
NaCNBH4 
 
T=40 oC 
 
Figure 3: Surface modification of solid lipid microparticles (SLM) using linear-PEI 
 
 
 
 
 
4.6 Encapsulation efficiency of SLM 
The encapsulation efficiency of lipid microparticles was determined by 
complete drug recovery from melted microparticles, followed by comparison with the 
theoretical maximum drug loading.  For microparticles containing rhodamine-B, 
encapsulated drug was recovered from 5.0 mg of lipid particles by melting in 1-ml of 
phosphate buffered saline (PBS) at five degrees above the corresponding lipid melting 
point. The resulting emulsion was cooled to room temperature and any re-solidified 
particulate matter was removed by centrifugal filtration (Ultrafree-MC, Millipore). 
The concentration of rhodamine-B in the supernatant was quantified in a microplate 
spectrofluorometer (Spectramax GeminiEM; Molecular Devices, Sunnyvale, CA) 
using 96-well black assay plates (Corning, Inc). The excitation and emission 
wavelengths were 540 nm and 625 nm, respectively. Complete recovery of nile-red 
from particles was performed in a similar fashion, with the exception that particles 
were melted in ethanol due to the insolubility of nile red in PBS.  The excitation and 
emission wavelengths of nile red were 550 nm and 650 nm, respectively.  
4.7 In vitro drug release 
In vitro drug release was determined by suspending 5.0 mg of microspheres in 
1-ml of PBS in amber microcentrifuge tubes (Eppendorf) and incubating at 37 
oC with   17
rotation (60 rpm). For rhodamine-B, samples were filtered, and the fluorescence was 
quantified in a microplate spectroflurometer at each given time interval. Rhodamine-B 
loaded samples were discarded after each time interval reading, thus each data point 
represents three dedicated samples. In the case of nile red, samples were first 
centrifuged (16,000 RCF) to pellet solids. The supernatants were then removed for 
fluorescence measurements, and pellets were resuspended in fresh buffer and allowed 
to rotate until the next time interval.  
4.8 Statistical Analysis 
  The statistical significance of experimental results was examined using the two 
sample Students’ t-test with p<0.05. The calculated errors were set to standard mean 
error for all experimental results.   18
CHAPTER 5. 
RESULTS AND DISCUSSION 
5.1. Lipid characterization 
Symmetrical 1,3-diglycerides were successfully synthesized following the 
McCrae[17] synthetic route with a yield in excess of 70%. Acyl chlorides were chosen 
such that the final product was a physiological lipid, for example palmitoyl chloride 
derived from palmitic acid, a fatty acid freely present in various metabolic pathways, 
was selected to synthesize C16 lipid and so on (Table 2). In addition, to derivation from 
physiological molecules, all of the synthesized lipids have melting points that are 
above room temperature making them ideal candidates for use as powder or 
particulates in drug delivery. 
Table 2: Lipids and their corresponding acyl chloride 
 
Elemental analysis results for C12-C18 lipids showed results within acceptance 
range, (Table 3). Proton nuclear magnetic resonance (
1H NMR) was also utilized to 
further characterize the products. Chemical shifts (δ) were measured in ppm using 
deuterated chloroform, CDCl3 as solvent.     19
Table 3: Lipids elemental analysis results and corresponding melting points 
 
 
Figure 4: 
1H-NMR spectra of C12  lipid (dodecanoic acid 3-dodecanoyloxy-2-oxo-
propyl ester) C12 lipid’s spectra serves as a representative of the remaining lipids. 
5.2 SLM characterization 
5.2.1 Size 
Particle sizes were measured using scanning electron microscopy (SEM) 
images that were obtained at low voltage (5 kV). Sizing results collected from 
multiple image analyses using Image J software showed polydisperse particle 
distributions in the micron size range. The effect of lipid concentration and surfactant   20
concentration on the final particle size with constant stirring rate and temperature was 
determined by serial variation of both parameters. The results showed that increasing 
the lipid concentration led to an increase in mean diameter (Figures 5 and 6), whereas 
increasing the surfactant concentration did not significantly change particle size 
(Figures 7 and 8). Statistical significance of particle size as a function of lipid chain 
length was inconclusive because of the polydispersity of the particle size distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Effect of pre-emulsion lipid solution concentration on particle size for a 
constant 2.5% PVA concentration. Error bars represent ±SEM. 
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Figure 6: Effect of pre-emulsion lipid solution concentration on particle size for a 
constant 5% PVA concentration. The mean particle diameter for high concentration 
C12 lipid, as well as C10 and C8 is statistically significant from its low concentration 
counterpart (n=3, p<0.05, ±SEM), indicated by asterisks (*). 
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Figure 7: Effect of varying PVA concentration with constant high pre-emulsion lipid 
solution concentration. At high concentration (0.02 g/ml), the mean particle diameter 
of C12 lipid sample decreases with increasing surfactant concentration, and is 
statistically significant (n=3, p<0.05, ±SEM), denoted by an asterisk (*). 
 
 
 
 
 
   23
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Effect of varying surfactant concentration with constant low pre-emulsion 
lipid solution concentration. At low concentration (0.01 g/ml), mean particle diameter 
for C8 lipid sample and C10 lipid sample as well as C14 and C16 diameters decreases 
with increasing surfactant concentration, and is statistically significant (n=3, p<0.05, 
±SEM) as indicated by asterisks (*). 
5.2.2 Morphology 
The particle surfaces were irregular with unique patterns depending on the 
lipid chain length. In spontaneous emulsification, the solvent must diffuse out into the 
external aqueous phase first prior to evaporation.  The irregular surface morphology of 
the lipid particles may therefore be a result of rapid solvent removal, leading to local 
precipitation or crystallization of the lipids [1].  Further inspection of the particle 
surfaces revealed that the morphology is distinct for each lipid chain length. The 
smaller lipids (C8 and C10) show a relatively smooth surface compared to C12 through 
C16. Additionally, the surface structures become more prominent as the lipid chin 
length increases (Figure 9).   24
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Clockwise from top-left, (A) C8 particle morphology showing a 
smooth surface followed by (B) C10,, (C) C12, (D) C14, and (E) C16. Note the 
increasing porosity with increasing lipid chain length.   25
5.2.3 Charge 
Zeta potential measurements showed that the SLMs are negatively charged in a 
1:10 dilution of PBS in water. The results indicate the presence of hydrolyzed ester 
groups on the surface. Along with hydroxyl PVA side chains, the ester groups of the 
diglycerides likely rearrange in such manner to associate with the aqueous phase. 
Upon removal of the organic solvent, these ester groups remain exposed on the surface 
of the newly formed lipid particles, leading to their hydrolysis and exposure of 
negatively charged carboxyl groups (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Zeta potential of lipid microparticles in 1:10 dilutions of PBS:Water.  
All lipid particle surfaces retain a negative charge. 
 
5.3. Surface modification of SLMs 
Particle surface modification provides the framework for targeted delivery of 
drugs. A myriad selection of literature discusses successful conjugation of functional 
groups to the surface of particles, for example Zanta et al. [31] successfully   26
conjugated galactose to branched PEI via imine formation with lactose and subsequent 
condensation of PEI-gal with plasmid DNA forming neutral galactose-bearing 
complexes. The PEI-gal complexes were further tested for in vitro gene delivery to 
liver (hepatocytes). Following the footsteps of Zanta et al., the modified synthetic 
route was used to conjugate linear-PEI onto the surface of lipid microparticles, (Figure 
3 and Scheme 2).  
Initial zeta potential measurements showed that lipid particle are negatively 
charged, the negative charge is attributed to the presence of hydrolyzed carbonyl 
groups on the surface. Zeta potential measurements acquired after the reaction with 
linear-PEI showed a positive surface charge. The first positive control experiment 
consisted of incubation of lipid in PBS medium for reaction duration, and the second 
positive control experiment consisted of incubation of lipid with linear-PEI in the 
absence of NaCNBH4, followed by zeta potential measurements. In the negative 
control experiment PLGA particles replaced their lipid counter parts and underwent 
the reaction with identical conditions. The positive control experiments suggest that 
linear-PEI interacts with the exposed carbonyl groups both covalently as well as 
electrostatically. Surface zeta potential was slightly less positive for particles that 
underwent 4× wash with 1M NaCl compared to the ones washed with DI-H2O, the 
reduction in zeta potential is due to removal of electrostatically attached linear-PEI 
onto the surface. The negative control experiment with PLGA particles showed that 
linear-PEI does not interact with carboxyl groups present on the surface covalently, 
however the electrostatic interaction between linear-PEI and the negative PLGA 
surface is quite strong.  The results of the Students’ t-test analysis showed that 
resulting surface charge is statistically significant between different chain lengths, the 
zeta potential becomes more positive as the lipid chain length increases. Another 
interesting observation was the results of the reaction between lipid particles and   27
linear-PEI in the absence of NaCNBH4; however more rigorous experiments are 
required to explain the observed behavior, (Figures 11 and 12). 
Recent drug delivery approaches have employed various synthetic routes for 
covalent attachment of moieties with positive charge. The increased interest in 
cationic particles stems firstly from the large population of therapeutics molecules 
such as DNA, oligonucleotides, and proteins are negatively charged, thus the 
electrostatic interaction between the two could stabilize the complex and lead to 
uptake by target cells. Secondly, a positively charged complex will maintain contact 
with the negatively charged outer cell membrane and thus will enable efficient 
internalization of the particle [32]. A vast variety of literature have reported successful 
functionlization of polymeric particles with linear and branched PEI, likewise our 
initial attempts to functionalize the surface of lipid particle have been successful 
however further characterization of the cationic lipid particle still remains.   
 
 
 
 
 
 
 
 
 
 
Scheme 2: Reductive amination reaction pathway 
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Figure 11: Results of reductive amination reaction of linear-PEI with C12 lipid in 
presence of NaCNBH4 and corresponding control experiments. Columns marked by * 
are statistically significant from each other, (n=3, p<0.05). Negative control 
experiment with PLGA particles shows statistical significance in zeta potential with 
NaCl wash versus water wash, NaCl (1M) solution washes remove electrostatically 
attached linear-PEI onto the surface and indicates the lack of covalent bonding 
between linear-PEI and carboxylic acid groups present on the surface of PLGA 
particles. Positive control experiment results shows zeta potential intensity of C12 lipid 
particles are statistically significant compared to those that underwent the reductive 
amination reaction with linear-PEI. The resulting zeta potential intensity of particles 
that underwent C12-PEI reaction in the absence of NaCNBH4 is also significant from 
those that underwent the reaction in presence of NaCNBH4, the difference can be 
contributed to changes in pH of the reaction environment, (n=3, p<0.05, ±SEM) 
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Figure 12: Results of reductive amination reaction for C12-C16 particles. Columns 
marked by * are statistically significant. The zeta potential intensity increases as the 
lipid chain length increases, the difference between the lipids’ zeta potential intensity 
is apparent after the reaction with linear-PEI, (n=3, p<0.05, ±SEM). 
5.4. Encapsulation Efficiency Measurements 
Rhodamine-B (hydrophilic model drug) and nile red (hydrophobic model drug) 
were successfully encapsulated in lipid particles, although with very different 
efficiencies. For rhodamine-B loaded particles, the encapsulation efficiency was less 
than 10 percent, whereas for nile red the efficiency exceeds 70 percent (Figures 13 and 
14). Factors that impact encapsulation efficiency range from the method of preparation 
to the nature of interaction between the model drug and the encapsulating matrix. Low 
encapsulation efficiency in the case of rhodamine-B can be attributed to the   30
hydrophobicity of the lipid matrix, the porous nature of the lipid microparticles, as 
well as the solubility of rhodamine-B in the aqueous PVA solution. Amongst all 
lipids, C8 with the shortest lipid chain displayed the highest encapsulation efficiency of 
rhodamine-B.  
For nile red the results are very different. All lipids encapsulated significant 
amounts of nile red (>70%). Additionally the Students’ t-test analysis of encapsulation 
efficiency for nile red loaded lipid particles showed that the difference between the 
lipids is not statistically significant (p>0.05). The high encapsulation efficiency in the 
case of nile red is attributed to a more favorable interaction between the hydrophobic 
model drug and the encapsulating lipid matrix.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Encapsulation efficiency for rhodamine-B loaded lipid particles. Columns 
marked by asterisk (*) are statistically significant. Encapsulation efficiency of lipids 
C10-C16 show statistical significance for encapsulation of rhodamine-B model drug, 
(n=9, p<0.05, ±SEM). No particular trend is observed between encapsulation 
efficiency and lipid chain length. Lipids show distinct crystallization behavior and   31
smooth morphology in case of shorter chain length lipids (C8-C10), a possible 
explanation for high encapsulation efficiency of C8 compared to longer chain length 
lipids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Encapsulation efficiency for red nile loaded lipid particles. Encapsulation 
efficiency results for lipids C8-C16 for nile red (hydrophobic model drug) show high 
values of more than 70%.  
5.5. In vitro controlled release behavior 
The in vitro release curves were created using measurements conducted at 37- 
oC for rhodamine-B as well as for nile red over a period of 24 hours. Results for 
rhodamine-B containing lipid microspheres show a burst release showing an expulsion 
of approximately 5-50% of encapsulated rhodamine-B over the initial hours [33]. This 
immediate release of the drug is attributed partly to the drug molecules associated with 
particle surface, or those entrapped in an outer thin shell of particle and partly due to   32
porous morphology of lipid particles. In contrast, the in vitro release curves for red 
nile samples showed slower release of 5-15% of the encapsulated nile red over the 
initial hours, in addition, longer chain length lipids (i.e. C14-C16) showed faster release 
compared to shorter chain lipids (i.e. C8-C12), (Figures 15 and 16). There are two 
possible explanations for the observed release behavior, firstly the release behavior is 
an approximate indication of nile red’s distribution in the lipid matrix, with nile red’s 
presence deeper in the core of the particle in case of smaller lipids, thus displaying 
slower release. In contrast, in case of larger lipids nile red is distributed closer to the 
surface and subsequently shows faster release. Secondly, slower release of smaller 
lipids maybe due to their smaller particle size, however particles prepared using 
solvent emulsification evaporation method are polydispersed, thus making it difficult 
to evaluate the effect of particle size on release profile confidently. A key determinant 
of drug release and degradation is the particle size [34], larger particle size leads to 
smaller surface:volume ratio thus leading to decreasing release rates. In addition 
during the fabrication process, smaller particles harden faster thus impacting the drug 
distribution within the lipid matrix. Noting the strong influence of the above factors, it 
becomes more difficult to obtain conclusive results regarding the existing interactions 
between the model drug and encapsulating matrix when varying surface:volume ratio 
amongst the particles themselves and from one lipid sample to another introduces a 
large and undesirable variability. Thus it becomes more essential to explore alternative 
means of particle fabrication that produce monodisperse particles in advance of in 
vitro release experiments. 
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Figure 15: Release of rhodamine-B from lipid microparticles. All lipids display burst 
release characteristics in the initial few hours of experimental time course, (n=3, 
±SEM). The observed trends between rhodamine-B release and lipid chain length are 
unclear. 
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Figure 16: Nile red release from lipid microparticles. All lipids display slow release 
for the duration of 24 hours (n=3, ±SEM). Release rates increase with increasing lipid 
chain length.   35
CHAPTER 6. 
CONCLUSION AND FUTURE DIRECTIONS 
A family of DHA derived symmetrical 1,3-diglcyerides with various 
hydrocarbon chain length were successfully synthesized and used to produce solid 
lipid microspheres via solvent emulsification-evaporation. Zeta potential 
measurements showed that the spheres are negatively charged and are susceptible to 
Schiff base reaction or reductive amination reaction with primary and secondary 
amines on the surface. Size measurements showed that particle distribution have a 
high polydispersity index, thus making it difficult to effectively measure encapsulation 
efficiency as well as in vitro controlled release profile.    
In an effort to resolve the aforementioned difficulties, alternative fabrication 
methods will be pursued to lower the polydispersity index of size distribution, thus 
allowing confident measurements of encapsulation efficiency. Studies have attributed 
the low drug encapsulation to formation of a perfect crystal lattice with few 
imperfections, thus leaving little or no room to accommodate drug molecules. A 
possible solution to this problem is to mix different lipids or make use of more 
complex lipid with different chain length thus inhibiting the formation of a perfect 
crystal lattice.  
In an attempt to determine drug distribution inside the lipid matrix, Confocal 
microscopy will be utilized to provide us with a visual evidence of model drug 
residence inside the lipid matrix. In addition, differential scanning calorimetry (DSC) 
of drug encapsulated lipids will clarify whether drug and the lipid matrix are phase 
immiscible leading to low drug encapsulation efficiency. In addition to the above 
experiments, a modified hot homogenization method will be utilized to assess the rate   36
of release of a model drug, as well as size and morphology as a function of preparation 
method.  
In conclusion, more studies are needed to evaluate the potentials of DHA-
derived solid lipid particles as excipient for controlled drug delivery, however initial 
experimental show great promise as functional biomaterials compared to polymeric 
particles and liposomes.   37
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